title: Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
abstract: BACKGROUND
  5-ASA-MMX (1.2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of 5-ASA-MMX (2.4 g/day, once daily), compared with Asacol (2.4 g/day, twice daily) in the maintenance of left-sided UC, through a double-blind, double-dummy, parallel-group, randomized, comparator study.
  
  
  METHODS
  In all, 331 patients with UC were randomized to receive either 5-ASA-MMX 2.4 g/day, once daily, or Asacol 2.4 g/day, twice daily, for 12 months. All patients were in remission for >or=1 month prior to the trial, with >or=1 documented relapse in the previous year. The co-primary endpoints of this study were the proportion of patients in clinical, and clinical and endoscopic remission following 12 months' treatment.
  
  
  RESULTS
  In the intent-to-treat population, excluding those with major protocol deviations, 68.0 and 65.9% patients in the 5-ASA-MMX and Asacol groups, respectively, were in clinical remission (P = 0.69), and 60.9 and 61.7% of patients, respectively, were in clinical and endoscopic remission (P = 0.89). Diary card data revealed statistically significant treatment differences favouring 5-ASA-MMX. Both treatments were similarly tolerated.
  
  
  CONCLUSIONS
  Once-daily 5-ASA-MMX is similarly effective with a comparable safety profile to Asacol administered twice daily, for the maintenance treatment of ulcerative colitis.
authors.affiliation: Department of Gastroenterology, Azienda Osp. S. Camillo-Forlanini, Rome, Italy. prantera@tin.it
authors.forename: C
authors.initials: C
authors.lastname: Prantera
authors.forename: A
authors.initials: A
authors.lastname: Kohn
authors.forename: M
authors.initials: M
authors.lastname: Campieri
authors.forename: R
authors.initials: R
authors.lastname: Caprilli
authors.forename: M
authors.initials: M
authors.lastname: Cottone
authors.forename: F
authors.initials: F
authors.lastname: Pallone
authors.forename: V
authors.initials: V
authors.lastname: Savarino
authors.forename: G C
authors.initials: GC
authors.lastname: Sturniolo
authors.forename: M
authors.initials: M
authors.lastname: Vecchi
authors.forename: A
authors.initials: A
authors.lastname: Ardia
authors.forename: S
authors.initials: S
authors.lastname: Bellinvia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010349:Patient Compliance; D012008:Recurrence; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D019804:Mesalamine